NCT Number: NCT00093275
HP184 in Chronic Spinal Cord Injury Subjects
The purpose of this study is to determine whether HP184 is effective in the treatment of chronic spinal cord injury (CSCI).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
sanofi-aventis administrative Australia & New-Zealand administrative office, Macquarie Park, New South Wales, Australia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male and female subjects with incomplete (traumatic), chronic (defined as 18 months or more post spinal cord injury) SCI aged 18 to 65 years
- CSCI must be categorized in classes C or D in the ASIA impairment scale. (C = Incomplete impairment with motor function preserved below the neurological level, and more than half of key muscles below the neurological level have a muscle grade less than 3. D = Incomplete impairment with motor function preserved below the neurological level, and at least half of key muscles below the neurological level have a muscle grade more than or equal to 3).
- The level of the SCI must be between C4 and T10 (neurological)
- Subject has a measurable range of motion at the hips, knees and ankles and possesses potential propulsive activity (i.e. no functional contractures)
- Female subjects of childbearing potential (those who are not surgically sterile or who are less than 2 years postmenopausal) must be using two forms of birth control, including a primary and a secondary form and have a negative pregnancy test immediately prior to treatment. Primary forms of contraception include: tubal ligation, partner's vasectomy, intrauterine devices, birth control pills, and topical/injectable/implantable/insertable hormonal birth control products. Secondary forms of contraception include diaphragms, latex condoms and cervical caps; each must be used with a spermicide.
Exclusion criteria
- Any clinical evidence of recent fracture(s) within the last six months prior to study start.
- Any history of Multiple Sclerosis or peripheral demyelinating disease or neuromuscular disorder.
- Heart rate of less than 38 or greater than 100
- Ashworth spasticity score of 0/4 or 4/4 at the hip or knee.
- Subject whose medical condition requires mechanical ventilation.
- Lower motor neuron injury, such as those with conus medullaris or cauda equina injuries.
- Subject with lower extremity amputation or proximal femorectomy.
- Subject with pressure ulcers stages 3 and 4.
- Subject medically or mentally unstable in judgment of Investigator.
- Subject on tricyclic antidepressants such as nortriptyline, amitriptyline and imipramine.
- Subject with ASIA motor score of greater than or equal to 92.
- Subject with ASIA sensory score of greater than or equal to 200.
- Subject with history of seizure within 2 years prior to study start.
- Subjects who have participated in a clinical trial involving investigational medication within 30 days prior to administration of HP184 or placebo.
- Female subjects with positive urine pregnancy test.
- Female subjects who are breast feeding.
Treatment and study plan
Primary outcomes
-
Change from baseline in total motor score of American Spinal Injury Association (ASIA) manual motor test at Week 24.
Secondary outcomes
-
Safety evaluation.
Sponsors and collaborators
Lead sponsor
Sanofi
Industry
Registry information
Official study title
A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of HP184 Administered Orally Once Daily for Twenty-Four Weeks in Adult Subjects With Chronic Spinal Cord Injury (CSCI)
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Oct 7, 2004
- Registry last updated
- Aug 21, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Turkish Version of the Neurogenic Bladder Symptom Score Short Form
NCT07507331
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsSpinal Cord Stimulation for Spinal Cord Injury Patients - Regain Walk and Alleviate Pain
NCT05433064
Central Nervous System Diseases, Nervous System Diseases
Hualien City, Taiwan
View Trial DetailsEpidural Stimulation and Rehabilitation for Spinal Cord Injury
NCT07717606
Central Nervous System Diseases, Conus Medullaris Injury
Istanbul, Turkey (Türkiye)
View Trial DetailsAssessing Transition Practices for Children With Disabilities: Pathways to a Successful Adulthood
NCT07706517
Brain Damage, Chronic, Brain Diseases
Saint-Etienne, France
View Trial Details